Research Article
The “CROMa” Project: A Care Pathway for Clinical Management of Patients with Bisphosphonate Exposure
Table 3
Data from CROMa database.
| CROMa patients | 502 | | Males | 99 | Females | 403 | Age | 8–90 | Paediatric | 11% | Adults | 89% |
| | |
Number |
| Osteometabolic diseases (OMD) | 79% (398) | | Postmenopausal osteoporosis | 310 | Osteogenesis imperfecta | 54 | Osteopenia | 13 | Osteoarthritis | 7 | Secondary osteoporosis | 6 | Glucocorticoid-induced osteoporosis | 3 | Fibrous dysplasia | 2 | Paget's disease | 1 | Other | 2 |
| | | Number |
| Metastatic cancer (CA) | 21% (104) | | Prostate cancer bone metastasis | 34 | Mammary cancer bone metastasis | 28 | Multiple myeloma | 14 | Renal cancer bone metastasis | 11 | Pulmonary cancer bone metastasis | 9 | Other | 8 |
|
BP administration | BP therapy | 58 (11%) | NBP therapy | 444 (89%) | OS | 54% | IV | 31% | IM | 11% | Association | 3% |
| Patients with no BRONJ | 474 (94,42%) | Patients with BRONJ | 28 (5,58%) | BRONJ from oral BP | 11 | BRONJ from IV BP | 17 |
|
|